- $20.26bn
- $31.14bn
- $14.81bn
- 87
- 44
- 76
- 77
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 12.7 | ||
PEG Ratio (f) | 0.7 | ||
EPS Growth (f) | 22.27% | ||
Dividend Yield (f) | 3.15% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.65 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 39.12 | ||
Price to Sales | 1.35 | ||
EV to EBITDA | 20.75 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 1.2% | ||
Return on Equity | -2.38% | ||
Operating Margin | 1.62% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 11,362 | 11,673 | 12,146 | 14,506 | 14,813 | 15,226.72 | 15,742.64 | 5.94% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +16.59 | -8.13 | -1.09 | -37.96 | -1.75 | +88.61 | +7.68 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies and precision positioning devices. Its Pharmaceuticals segment includes specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. Its Kidney Care segment includes chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies (CRRT) and other organ support therapies.
Directors
- Jose Almeida CHM (58)
- James Saccaro CFO (48)
- Giuseppe Accogli COO (51)
- Sean Martin SVP (58)
- Jeanne Mason SVP (65)
- James Borzi SVP (58)
- Cristiano Franzi SVP (57)
- Andrew Frye SVP (55)
- Jacqueline Kunzler SVP (55)
- Albert Stroucken LED (73)
- Nancy Schlichting DRC (67)
- Thomas Chen IND (71)
- John Forsyth IND (73)
- Peter Hellman IND (71)
- Michael Mahoney IND
- Patricia Morrison IND (61)
- Stephen Oesterle IND (70)
- Cathy Smith IND (57)
- Thomas Stallkamp IND (74)
- Amy Wendell IND (61)
- David Wilkes IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 19th, 1931
- Public Since
- May 15th, 1961
- No. of Shareholders
- 19,117
- No. of Employees
- 60,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 510,177,606
- Address
- 1 Baxter Parkway,, DEERFIELD, 60015
- Web
- https://www.baxter.com/
- Phone
- +1 8479482000
- Contact
- Clare Trachtman
- Auditors
- PricewaterhouseCoopers LLP
Latest News for BAX
Upcoming Events for BAX
Q3 2024 Baxter International Inc Earnings Release
Q4 2024 Baxter International Inc Earnings Release
Similar to BAX
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
As of Today at 20:00 UTC, shares in Baxter International are trading at $39.72. This share price information is delayed by 15 minutes.
Shares in Baxter International last closed at $39.72 and the price had moved by +1.46% over the past 365 days. In terms of relative price strength the Baxter International share price has underperformed the S&P500 Index by -19.75% over the past year.
The overall consensus recommendation for Baxter International is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Baxter International dividend yield is 2.92% based on the trailing twelve month period.
Last year, Baxter International paid a total dividend of $1.16, and it currently has a trailing dividend yield of 2.92%.Looking ahead, the next dividend pay date is 2024-10-01.
We do not have data on when Baxter International is to next pay dividends. The historic dividend yield on Baxter International shares is currently 2.92%.
To buy shares in Baxter International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $39.72, shares in Baxter International had a market capitalisation of $20.26bn.
Here are the trading details for Baxter International:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BAX
Based on an overall assessment of its quality, value and momentum Baxter International is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Baxter International is $40.65. That is 2.34% above the last closing price of $39.72.
Analysts covering Baxter International currently have a consensus Earnings Per Share (EPS) forecast of $2.97 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Baxter International. Over the past six months, its share price has underperformed the S&P500 Index by -12.63%.
As of the last closing price of $39.72, shares in Baxter International were trading +4.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Baxter International PE ratio based on its reported earnings over the past 12 months is 12.7. The shares last closed at $39.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Baxter International's management team is headed by:
- Jose Almeida - CHM
- James Saccaro - CFO
- Giuseppe Accogli - COO
- Sean Martin - SVP
- Jeanne Mason - SVP
- James Borzi - SVP
- Cristiano Franzi - SVP
- Andrew Frye - SVP
- Jacqueline Kunzler - SVP
- Albert Stroucken - LED
- Nancy Schlichting - DRC
- Thomas Chen - IND
- John Forsyth - IND
- Peter Hellman - IND
- Michael Mahoney - IND
- Patricia Morrison - IND
- Stephen Oesterle - IND
- Cathy Smith - IND
- Thomas Stallkamp - IND
- Amy Wendell - IND
- David Wilkes - IND